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Most reports dealing with vaccines against botulinum toxin have focused on the injection route of
administration. This is unfortunate, because a mucosal vaccine is likely to be more efficacious for patients
and pose fewer risks to health care workers and to the environment. Therefore, efforts were made to
generate a mucosal vaccine that provides protection against the botulinum serotypes that typically cause
human illness (serotypes A, B, and E). This work demonstrated that carboxy-terminal peptides derived
from each of the three serotypes were able to bind to and penetrate human epithelial barriers in vitro, and
there was no cross inhibition of membrane binding and transcytosis. The three polypeptides were then
tested in vivo as a trivalent vaccine that could be administered to mice by the intranasal route. The results
indicated that the mucosal vaccine evoked high secretory titers of immunoglobulin A (IgA), as well as high
circulating titers of IgG and IgA, and it also evoked a high level of resistance to challenge with toxin. The
immunoglobulin responses and the levels of resistance to challenge were increased by coadministration of
adjuvants, such as chitosan and vitamin E. At least three mechanisms were identified to account for the
antibody-induced resistance: (i) blockade of toxin absorption across epithelial cells, (ii) enhanced clear-
ance of toxin from the circulation, and (iii) blockade of toxin action at the neuromuscular junction. These
results are a compelling demonstration that a mucosal vaccine against multiple serotypes of botulinum
toxin has been identified.
Botulinum toxin (BoNT) is a uniquely potent agent that is
synthesized by the organisms Clostridium botulinum, Clostrid-
ium beratii, and Clostridium butyricum. This toxin, which exists
in seven different serotypes (serotypes A to G) and more than
40 subtypes (30, 35), causes a serious and potentially life-
threatening disease called botulism (12, 14). This disease can
occur naturally, but it can also be a result of bioterrorism and
biological warfare (3).
All serotypes of BoNT are synthesized as relatively inactive
single-chain polypeptides with molecular masses of ca. 150
kDa. These precursors must undergo posttranslational modi-
fication (“nicking”), which yields dichain molecules in which a
light chain (LC) is linked by a single disulfide bond to a heavy
chain (HC). The three-dimensional structures of some of the
serotypes have been determined (17, 37). This work has re-
vealed that the molecule is composed of three lobes, which
represent LC, the amino-terminal portion of HC, and the car-
boxy-terminal portion of HC.
Considerable progress has been made in determining the
mechanism of toxin action, as well as the structure-function
relationships that govern this action (31, 32). Botulinum toxin
typically acts as an oral poison, although it can also be an
inhalation poison (27). The sequence of events is the same for
both routes of exposure (32). The toxin binds to the apical
surface of epithelial cells, undergoes endocytosis and transcy-
tosis, and then is released into the general circulation (1, 21,
22). A portion of the toxin escapes from the blood and lymph
and reaches the extracellular space, where it acts on peripheral
cholinergic nerve endings. The toxin molecule binds with high
affinity to the plasma membrane and then undergoes receptor-
mediated endocytosis and pH-induced translocation to reach
the cytosol. The toxin acts inside cells to cleave polypeptides
that are essential for transmitter release. Blockade of exocyto-
sis produces the muscle weakness and paralysis that are hall-
marks of the disease botulism (31, 32).
The fact that BoNT can produce a devastating disease, com-
bined with the fact that it is a potential bioterrorism and
biological warfare agent, has sparked intense efforts to develop
a vaccine. Most current work on a botulism vaccine can be
traced to previous preclinical studies of an injectable tetanus
vaccine. The tetanus toxin molecule, like the BoNT molecule,
is a protein with a molecular mass of ca. 150 kDa (4, 11, 28). It
too is composed of three domains that can be designated LC,
the amino-terminal portion of HC, and the carboxy-terminal
portion of HC. Early studies of isolation and fragmentation of
the tetanus toxin molecule led to the discovery that limited
proteolysis combined with disulfide bond reduction produced
two polypeptides: (i) LC linked to the amino-terminal portion
of HC and (ii) the carboxy-terminal portion of HC. The latter
was shown to be an efficacious parenteral vaccine against tet-
anus toxin (10, 13, 20).
Investigators in the BoNT field have subsequently generated
the carboxy-terminal portion of HC, both by limited proteol-
ysis of the wild-type toxin and by recombinant techniques. This
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polypeptide domain has been shown to be an injectable vaccine
that is effective against the parent toxin (5, 6).
In a completely different line of research, an effort has been
made to identify the minimum essential domain of the BoNT
molecule that is needed for binding and penetration of gut and
airway epithelial cells (23). This work has demonstrated that (i)
the BoNT molecule by itself contains the information for bind-
ing and transcytosis across epithelial monolayers, and there is
no need for auxiliary proteins that bacteria release in associa-
tion with the toxin; (ii) both LC and the amino-terminal por-
tion of HC can be removed from the holotoxin, and the resid-
ual carboxy-terminal domain is able to cross epithelial barriers;
and (iii) the carboxy-terminal domain that undergoes binding
and transcytosis retains all of its characteristic structural and
functional properties (1, 21–23).
The different lines of research on the BoNT molecule
have coalesced in what may be an exciting coincidence of
findings. On the one hand, the carboxy-terminal end of HC
has the properties of an immunogen. On the other hand, the
same polypeptide has the ability to bind to and penetrate
epithelial barriers in the gut and airway. These findings
suggest that this molecule could be a mucosal vaccine
against botulism.
In this report, a substantial body of evidence is presented
to show that a mucosal vaccine against botulism has been
identified. In addition, this report is the first to describe a
recombinant trivalent vaccine against botulism, and it is the
first to identify and quantify the various layers of antibody-
induced protection against the toxin. Beyond this, the report
introduces novel adjuvants to the clostridial toxin field, and
it introduces the concept of a universal vaccine to the BoNT
literature.
MATERIALS AND METHODS
Toxin. Homogeneous BoNT type A (BoNT/A) was isolated from bacterial
cultures as previously described (9, 30, 34). Homogeneous BoNT/B and BoNT/E
were purchased from Metabiologics (Madison, WI). The homogeneity of the
preparations was confirmed by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) (18).
BoNT/A was isolated in a nicked and biologically active form. BoNT/B and
BoNT/E were isolated in the single-chain form and subsequently nicked. To
generate the two-chain form of these toxins, the single-chain molecules were
proteolytically activated with trypsin. To facilitate subsequent separation of the
toxin from the nicking enzyme, L-1-tosylamido-2-phenylethyl chloromethyl ke-
tone-treated trypsin cross-linked to 4% beaded agarose was used (immobilized
trypsin; Pierce Chemical, Rockford, IL). The trypsin slurry was washed three
times with reaction buffer (10 mM sodium phosphate buffer, pH 7.5). Toxin was
added and incubated with the enzyme at room temperature (21°C) for 1 h at a
ratio of trypsin to toxin of 1:10. After incubation, the nicked toxin was separated
from the beaded trypsin by filtration through a 0.2-m centrifugal filter (Centrex
microfilter unit; Schleicher & Schuell, Keene, NH). The nicked toxin was col-
lected, aliquoted, and stored at20°C until it was used. A sample of the material
was examined by electrophoresis to verify the degree of nicking and the integrity
of the dichain toxin.
Iodination. BoNT/A was iodinated using 125I-Bolton-Hunter reagent, essen-
tially according to the manufacturer’s instructions. Pure neurotoxin (300 g) in
200 l of borate buffer (pH 7.8) was added to dried iodinated ester and incubated
on ice for 15 min. The reaction was terminated by addition of 50 l of 1 M glycine
in borate buffer and incubation for 15 min. The total reaction mixture (250 l)
and rinse (250 l) were loaded onto a Sephadex G-25 column that was preequili-
brated with filtration buffer (150 mM Na2HPO4, 150 mM NaCl, 0.11% gelatin;
pH 7.4). The labeled toxin was eluted with filtration buffer, and 0.5-ml fractions
were collected. An aliquot (5 l) of each fraction was assayed to determine the
radioactivity. The labeled toxin peak, which eluted at the void volume, was
pooled and stored at 4°C. The toxin concentration in the pooled fraction was
determined spectrophotometrically at 278 nm using the following relationship:
1.63 A278 units  1 mg/ml (9).
Iodinated samples were assayed with a gamma-counter to determine the num-
ber of disintegrations per minute. Sample concentrations and associated counts
were used to calculate the specific activity.
Iodinated toxin purity and biological activity. The homogeneity of 125I-labeled
BoNT/A was determined by SDS-PAGE. The BoNT/A samples were separated
on a 10% polyacrylamide gel by the method of Laemmli (18). Gels were run
under nonreducing conditions and stained with Coomassie blue, followed by
drying under a vacuum (Bio-Rad Laboratories model 224 gel slab dryer) for 2 h.
The gels were exposed to Hyperfilm ECL (GE-Amersham Biosciences, Bucks,
United Kingdom) for 24 to 48 h and developed using a Kodak O-XMAT film
processor (Eastman Kodak Co., Rochester, NY). Developed film was ana-
lyzed to determine the presence of a 125I-labeled BoNT/A band (150 kDa).
BoNT/A was iodinated three times during the study, and the average specific
activity was 2.76  102 Ci/mmol. Each batch of toxin was used for ca. 60 days.
Aliquots of material that were used in individual experiments during this period
were subjected to additional chromatography (Sephadex G-25) prior to use to
ensure that free isotope and small polypeptide fragments were removed.
Nomenclature. According to accepted nomenclature (26), BoNT is the abbre-
viation for botulinum neurotoxin. LC is the accepted designation for the light
chain, and HC is the designation for the heavy chain. Unfortunately, there is no
accepted terminology for identifying polypeptides that represent HC fragments
that are various lengths. Therefore, in this report, a simple convention is used.
HC with a subscript indicates a polypeptide that begins at the carboxy terminus
of the HC and has the molecular mass (in kilodaltons) indicated by the subscript.
Thus, HC50 is a carboxy-terminal peptide that is derived from the HC and has a
molecular mass of 50 kDa.
Cloning, expression, and purification of recombinant HC50 domains of
BoNT/A, BoNT/B, and BoNT/E. Gene segments encoding the HC50 fragments of
BoNT/A (strain 62A; amino acids 861 to 1296), BoNT/B (strain Okra; amino
acids 853 to 1291), and BoNT/E (strain NCTC 11219; amino acids 840 to 1252)
were cloned into the vector pQE30 (QIAGEN, Germantown, MD), yielding
expression plasmids pQEHC50 A, pQEHC50 B, and pQEHC50 E, respectively.
Escherichia coli BL21-codon plus(DE3)-RIL (Stratagene, Cedar Creek, TX)
was used as the host strain for expression of HC50 domains. Cells were grown in
Terrific broth (1.2% peptone, 2.4% yeast extract, 0.94% K2HPO4, 0.22%
KH2PO4; Difco, Sparks, MD) at 37°C, with shaking to an A600 of 0.6 to 0.8.
Isopropyl--D-thiogalactopyranoside (IPTG) at a final concentration of 0.5
mM was added, and the culture was incubated for 12 h at 25°C. The bacteria
in 1 liter of an induced culture were harvested by centrifugation (6,000  g,
15 min) at 4°C.
Cells were suspended in 200 ml of bacterial protein extract reagent (Pierce,
Rockford, IL) at 4°C. Lysozyme (Sigma, St. Louis, MO) at a final concentration
of 0.1 mg/ml, DNase (Sigma) at a final concentration of 0.01 mg/ml, and a
protease inhibitor cocktail (Roche, Indianapolis, IN) were added to the cell
suspension and incubated on a rotating shaker for 2 h. Four hundred milliliters
of 50 mM sodium phosphate buffer containing 300 mM NaCl (pH 8.0) was added
to the lysed cell suspension and allowed to stand for 30 min. The suspension was
centrifuged at 27,000  g for 40 min to remove the precipitate.
The clear supernatant was loaded onto a 5-ml column of Ni-nitrilotriacetic
acid Superflow (QIAGEN) which was equilibrated with 50 mM sodium phos-
phate buffer containing 300 mM NaCl (pH 8.0). The column was washed with 50
volumes of washing buffer (50 mM sodium phosphate buffer containing 300 mM
NaCl and 20 mM imidazole; pH 8.0). Bound protein was eluted from the column
with an imidazole gradient (20 to 250 mM imidazole in 50 mM sodium phosphate
buffer containing 300 mM NaCl [pH 8.0]). The active fractions (which eluted
with 100 mM imidazole) were pooled and dialyzed against 50 mM sodium
phosphate (pH 6.8). The dialysate was centrifuged at 27,000  g for 30 min to
remove the precipitate.
The clear supernatant was loaded onto a cation-exchange column containing
4 ml of CM Sepharose Fast Flow (GE-Amersham Bioscience) equilibrated with
50 mM sodium phosphate (pH 6.8). The column was washed with 50 volumes of
50 mM sodium phosphate (pH 6.8). Bound protein was eluted from the column
with an NaCl gradient (50 to 500 mM NaCl in 50 mM sodium phosphate buffer
[pH 6.8]). The active fractions (which eluted with 200 mM NaCl) were pooled
and dialyzed against 50 mM sodium phosphate (pH 7.4). Approximately 15 to 20
mg of each HC50 polypeptide was obtained from 1 liter of bacterial culture. The
purity of the HC50 polypeptides was confirmed by 10% SDS–PAGE.
Western blot analysis. Rabbit and mouse antisera against HC50/A, HC50/B,
and HC50/E were prepared in our laboratory. For Western blotting, samples
were separated under reducing conditions by 10% SDS–PAGE using a Mini-
Protean III electrophoresis cell (Bio-Rad Laboratories, Hercules, CA). Proteins
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were then transferred to a Nitropure nitrocellulose membrane using a Mini
Trans-Blot electrophoretic transfer cell (Bio-Rad Laboratories) in Tris-glycine
transfer buffer at 75 V for 90 min, as described by Towbin et al. (38). Blotted
membranes were rinsed with phosphate-buffered saline–0.05% Tween 20
(PBST) (pH 7.5) and blocked with 5% nonfat powder milk in PBST at room
temperature. For identification of recombinant toxin fragments, the membranes
were washed three times with PBST and then incubated with the appropriate
antiserum at a 1:5,000 dilution in PBST with 0.5% nonfat powdered milk at
4°C overnight. The membranes were then washed three times with PBST and
incubated with secondary antibody at a 1:10,000 dilution in PBST with 0.5%
nonfat powder milk for 1 h at room temperature. After this the membranes
were washed three times with PBST at room temperature and visualized using
SuperSignal West Pico chemiluminescence (Pierce Chemical) according to
the manufacturer’s instructions. The membranes were exposed to Hyperfilm
ECL film (GE-Amersham Biosciences) for times adequate to visualize the
chemiluminescent bands. HC50 fragments were identified by comparison with
known protein standards.
Cell culture. T-84 human epithelial cells were grown in a l:1 mixture of
Dulbecco’s modified Eagle’s medium containing 1 g/liter D-glucose and Ham’s
F-12 nutrient medium supplemented with 5% newborn calf serum, 100 U/ml
penicillin, 100 g/ml ampicillin, and 15 mM HEPES. Cultures were maintained
at 37°C in 6% CO2. T-84 cells were fed every 3 days and passaged (1:2) when they
were 95% confluent, approximately every 6 days. Passages 65 through 90 were
used for experiments described below.
Transcytosis assay. Cells were grown in Transwell porous-bottom dishes on
polycarbonate membranes with a 0.4-m pore size. The growth area within each
insert was 1.12 cm2. The Transwells were coated with 10 g/cm2 rat tail collagen
type 1. The coated wells were allowed to dry at room temperature overnight (18 h).
After drying, the wells were sterilized under UV light for 1 h, which was followed
by preincubation with cell culture medium (30 min). The preincubation medium
was removed immediately before addition of cells and fresh medium.
T-84 cells were plated at a confluent density (ca. 1.5  105 cells) in the
Transwells with 0.5 ml of medium in the upper chamber and 1.0 ml of medium
in the lower chamber. The medium in the upper chamber bathed the apical (or
mucosal) surface of cells, and the medium in the lower chamber bathed the
basolateral (or serosal) surface of cells. The culture medium was changed every
2 days. The cultures were allowed to differentiate for at least 10 days before a
transcytosis assay was performed. The formation of tight junctions was confirmed
experimentally by measuring transepithelial electrical resistance. Experiments
were performed with cultures that were between 10 and 15 days old.
The transcytosis assay was initiated by adding BoNT or HC50 to the upper
chamber. Transport of these molecules was monitored for 18 to 20 h by collecting
all of the medium from the bottom chamber. An aliquot (0.5 ml) of each sample
was filtered through a Sephadex G-25 column, and 0.5-ml fractions were col-
lected. The amount of polypeptide that crossed epithelial monolayers was de-
termined in various ways, as described in Results.
Neuromuscular transmission. Mouse phrenic nerve-hemidiaphragm prepara-
tions were excised and placed in tissue baths to assay the toxicity of BoNT in
biological specimens (15). The tissues were suspended in physiological buffer
that was aerated with 95% O2 and 5% CO2 (33). Phrenic nerves were stimulated
continuously (0.2 Hz; 0.1- to 0.3-ms pulses), and muscle twitch was recorded.
Toxin-induced paralysis was defined as a 90% reduction in the muscle twitch
response to neurogenic stimulation.
Vaccination protocol. Animals (18- to 20-g female BALB/c mice; Charles
River Laboratories, Wilmington, MA) were immunized by the intranasal (i.n.)
route or by the intramuscular (i.m.) route. For the former route, individual
antigens or combinations of antigens (20 g each) were administered by a single
application of 20 l of a phosphate-buffered saline solution (pH 7.4) to the nares
of mice. For the latter route, antigens (5 or 20 g) were administered in a single
bolus (50 l) of a phosphate-buffered saline solution. In both cases, animals
received a prime dose at zero time and booster doses on days 14 and 28.
In some experiments, antigen was admixed with an adjuvant prior to admin-
istration. Two mucosal adjuvants (1% [wt/vol] chitosan and 5% [wt/vol] vitamin
E TPGS) and one parenteral adjuvant (0.2% [wt/vol] alum) were tested.
In addition to the traditional modes of vaccine administration (e.g., exclusively
i.n. or exclusively i.m.), one mixed mode of administration was tested. This
involved an initial or prime dose administered by the injection route and two
subsequent booster doses administered by the mucosal route. When an adjuvant
was included, alum was used for the prime dose and vitamin E was used for each
booster dose.
In all vaccination paradigms, biological specimens (blood and serum) were
collected on day 42. Within 1 to 5 days of specimen collection, animals were
challenged with BoNT. Survivors were monitored for 1 week, an amount of
time that exceeds the time necessary to detect 1 50% lethal dose (LD50) (96 h).
Enzyme-linked immunosorbent assay (ELISA). Antibody titers in mouse se-
rum were determined by standard procedures. Briefly, flat-bottom, 96-well Corn-
ing plates (Corning Incorporated, Corning, NY) were coated with the HC50
domains of BoNT (300 ng/well) and incubated at 4°C overnight, followed by
washing with phosphate-buffered saline containing 0.1% Tween 20 (pH 7.4). The
plates were blocked with 1% bovine serum albumin. Twofold serial dilutions of
serum samples were added to the plates and incubated at 37°C for 60 min.
Immunoglobulin G (IgG) titers were determined using peroxidase-conjugated
goat anti-mouse IgG (Sigma-Aldrich, Inc., St. Louis, MO), and IgA titers were
determined using peroxidase-conjugated goat anti-mouse IgA (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA). Secondary antibodies were diluted 1:1,000 in
phosphate-buffered saline. The primary and secondary antibodies were incu-
bated for 30 min at 37°C, after which 2,2	-azinobis(3-ethylbenthiazoline-6-sul-
fonic acid) was added as a substrate, and the plates were incubated for an
additional 30 min at 37°C. The end point titers were the reciprocals of the last
dilutions yielding an absorbance at 405 nm that was greater than the control
value (preimmune serum).
Antibody titers were also determined for bronchoalveolar lavage (BAL) sam-
ples from mice. Specimens were obtained by anesthetizing animals with pento-
barbital sodium (Nembutal; 50 mg/kg, given intraperitoneally [i.p.]). The com-
plete lung along with the trachea was excised, and BAL samples were collected
from individual mice by internal flushing through the trachea with cold 50 mM
phosphate-buffered saline (pH 7.6) containing Complete protease inhibitors
(Roche, Indianapolis, IN). The samples collected (1.5 ml per mouse) were then
centrifuged at 6,000 rpm at 4°C for 10 min. Supernatants were collected and
stored at 4°C for subsequent analysis.
The levels of antigen-specific secretory IgA in BAL samples were determined
using an ELISA kit (Bethyl, Montgomery, TX). Briefly, 96-well polystyrene
plates were coated with HC50 domains (100 l, 20 g/ml protein) in 0.05 M
carbonate-bicarbonate buffer (pH 9.6). The plates were incubated at 37°C for 1 h
and then overnight at 4°C. The plates were washed with buffer (50 mM Tris, 0.14
M NaCl, 0.05% Tween 20; pH 8.0) and blocked with 200 l of 1% bovine serum
albumin (Sigma) in Tris-NaCl buffer for 2 h at 37°C. After two washes with
buffer, 100-l portions of serially diluted BAL samples (starting at a 1:10 dilution
in Tris-NaCl-Tween 20 buffer containing 1% bovine serum albumin) were added
to the plates, which were incubated for 1 h at 37°C. The secretory IgA was
detected by adding 100 l/well of a 1:5,000 dilution of peroxidase-conjugated
goat anti-mouse IgA antibody. Color was developed by adding 100 l/well of a
1-mg/ml ortho-phenylenediamene substrate solution in sodium citrate buffer (pH
5.0) containing 2 l of 30% H2O2. After incubation for 15 to 20 min at room
temperature, the reaction was stopped using 50 l of 2 N H2SO4. The optical
density at 490 nm was determined using an ELISA reader (VERSA max; Mo-
lecular Devices).
Challenge with toxin. The most characteristic outcome of BoNT action is
neuromuscular blockade. This outcome is easily discernible as weakness and
eventual paralysis of the muscles of locomotion and the muscles of respiration.
During bioassays of resistance, as well as the associated experiments with anti-
serum, animals received doses of toxin sufficient to produce paralysis of respi-
ration and death within minutes (ca. 100 to 120 min). To minimize the pain and
suffering, animals were observed throughout the various protocols. When signs of
neuromuscular weakness became obvious, animals were sacrificed in accordance
with AAALAC guidelines (e.g., with CO2).
Blood and organ levels of toxin. Iodinated BoNT/A was administered intra-
venously to mice via the tail vein, and 30 min later specimens were obtained by
retroorbital bleeding. Experiments were performed using control animals (toxin
only) and experimental animals (toxin preincubated with antiserum from vacci-
nated animals). The goal of the experiments was to determine the extent of toxin
clearance in animals that had a circulating titer of antibody adequate to com-
pletely neutralize the dose of toxin administered.
In addition to monitoring the levels of toxin in blood, one set of experiments
determined the extent of local toxin accumulation in tissues. Mice were anes-
thetized by administration of pentobarbital sodium (50 mg/kg), after which the
thorax was opened and the heart was exposed. A butterfly needle (23 gauge) was
inserted into the left ventricle, an incision was made in the right ventricle, and the
body of the animal was perfused with a heparinized solution of phosphate-
buffered saline (45 to 60 ml). Six major organs were removed from the body
(liver, spleen, kidney, lung, brain, and heart), and the accumulation of iodinated
toxin was determined.
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RESULTS
BoNT/A HC50 is a mucosal vaccine. In previous work, an
effort has been made to identify the minimum essential domain
of the BoNT molecule that retains full competence to bind to
and penetrate human gut and airway epithelial cells. To date,
this work has demonstrated that HC, HC88, HC66, and HC50 of
BoNT/A all have within them the properties of a minimum
essential domain (22, 23). In a parallel series of experiments,
an effort has been made to identify an antigen that can act by
the mucosal route (oral and/or inhalation) to evoke resistance
to homologous toxin. This work has demonstrated that a mod-
ified botulinum holotoxin with point mutations in the histidine
motif (15), as well as a full-length HC without modifications
(27), can act as mucosal vaccines.
The current studies are a continuation of previous work on
a minimum essential domain for binding and transcytosis and
on an immunogenic domain that can act by the mucosal route
to evoke resistance. Thus, BoNT/A HC50 is a rational choice
for evaluation as a potential i.n. vaccine. Mice (n  10) were
vaccinated with this polypeptide i.n. (20 g in 20 l) at time
zero, 14 days, and 28 days. Fourteen days after the final boost,
aliquots of blood were obtained to determine the circulating
levels of antibody. The results of the ELISA, which are shown
in Fig. 1, demonstrate that there was a substantial IgG re-
sponse and a more modest IgA response.
Both control animals and vaccinated animals were chal-
lenged i.p. with BoNT/A (1  103 LD50 in 50 l). As expected,
control animals became seriously ill within a short time (100
min or less). Vaccinated animals survived the challenge, and
there was never any evidence of illness.
The addition of an adjuvant enhances the immunoglobulin
response to BoNT/A HC50. Mice (10 mice per group) were
vaccinated with BoNT/A HC50 as described above in the ab-
sence or presence of an adjuvant. As described in Materials
and Methods, two types of adjuvants were tested (chitosan and
vitamin E). As shown in Fig. 2, both chitosan and vitamin E
increased the levels of the immunoglobulin responses. The
results of a quantitative comparison of the immunoglobulin
responses in the absence and presence of adjuvant are shown
in Table 1.
The results of the i.p. challenge experiments (1 103 mouse
LD50 in 50 l) were identical to those described above. Thus,
control animals succumbed to the effects of toxin within ca. 100
min, but vaccinated animals never developed signs of botulism,
even when they were monitored for an extended time (1
week).
BoNT HC50, in the absence or presence of an adjuvant, can
function as an injection vaccine. Several investigators have
shown that the HC50 domains of tetanus toxin and BoNT can
evoke immunity to the parent holotoxins (see the introduction
for references). This work typically involved administration of
FIG. 1. Immunoglobulin responses to the HC50 domain of
BoNT/A. The polypeptide was administered to mice (n 10) as an i.n.
vaccine. Two weeks after the second booster, the dilution titers for IgG
(‚) and for IgA () in serum were determined. The data show that
mucosal vaccination evoked circulating titers of both antibodies.
FIG. 2. Immunoglobulin responses to the HC50 domain of BoNT/A
when it was coadministered with an adjuvant. (a) The polypeptide was
administered to mice (10 mice per group) as an i.n. vaccine with
chitosan (f) or with vitamin E (F), and the magnitudes of the IgG
responses were determined. (b) The polypeptide was administered to
mice (10 mice per group) as an i.n. vaccine with chitosan (}) or with
vitamin E (Œ), and the magnitudes of the IgA responses were deter-
mined. The adjuvants enhanced the responses to both immunoglobu-
lins, but the effect with IgA was greater. This was probably a reflection
of the fact that the response to IgA in the absence of adjuvant (see Fig.
1) was lower.
TABLE 1. Fifty percent dilution titers of sera from mice
vaccinated with BoNT/A HC50
Adjuvant
Immunoglobulin titers
IgG IgA
None 1:4,000 1:800
Chitosan 1:10,000 1:40,000
Vitamin E 1:20,000 1:80,000
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an adjuvant (alum) (see Materials and Methods) but did not
typically involve measurement of circulating IgA titers. There-
fore, mice (n  10) were vaccinated by i.m. injection (5 g
BoNT/A HC50 in 50 l) in the absence or presence of an
adjuvant (alum). Fourteen days after the second booster, ali-
quots of blood were obtained for determination of the immu-
noglobulin responses. In addition, animals were challenged
with holotoxin by the i.p. route.
In the absence of the adjuvant the HC50 polypeptide evoked
a strong IgG response, and in the presence of the adjuvant this
response was somewhat elevated (Fig. 3a). In the absence of
the adjuvant there was a modest IgA response, but in the
presence of the adjuvant there was a strong response (Fig. 3b).
Two types of challenge experiments were performed. Vac-
cinated animals that did not receive an adjuvant, as well as the
matched controls, were challenged i.p. with 1  103 mouse
LD50 (50 l). As described above, all control animals were
seriously ill after 100 min or less. All vaccinated animals sur-
vived without any signs of illness for 1 week. Vaccinated
animals that received the adjuvant, as well as matched controls,
were challenged i.p. with 1  104 mouse LD50 (50 l). Again,
the control animals were clearly ill within a matter of minutes,
whereas the vaccinated animals survived without illness for an
extended time (1 week).
HC50 domain of BoNT/A can function as a mixed-mode
vaccine. The most rational approach for vaccine administration
may not be solely by the injection route or solely by the mu-
cosal route. A realistic alternative may be to use a combination
of the two. Therefore, mice were vaccinated by combining an
initial injection (20 g of antigen in 50 l physiological saline,
given i.m.) at time zero with two boosters (20 g of antigen in
20 l physiological saline, given i.n.) at 14 and at 28 days. Alum
was used as the adjuvant for the initial injection, and vitamin E
was used as the adjuvant for the subsequent i.n. boosters.
Fourteen days after the final booster, aliquots of blood were
obtained to determine the circulating titers of IgG and IgA. As
shown in Fig. 4, the mixed mode of vaccine administration
evoked substantial responses for both classes of immunoglob-
ulin. The magnitudes of these responses were comparable to
the magnitudes observed after i.m. injection alone (Fig. 3) and
after i.n. administration alone (Fig. 2).
Vaccinated animals and control animals were challenged i.p.
with the holotoxin (1  103 mouse LD50 in 50 l), and the
results were consistent with the results described above. All
control animals succumbed to the poison within minutes (120
min or less), and all mixed-mode-vaccinated animals survived
without signs of illness for 1 week.
BoNT/B HC50 and BoNT/E HC50 can bind to and penetrate
monolayers of human epithelial cells. The HC, HC88, HC66,
and HC50 domains of BoNT/A have all been shown to cross
barriers formed by immortalized human epithelial cells (T-84
and Caco-2) (1, 22, 23), as well as barriers formed by primary
human epithelial cells (A. B. Maksymowych and L. L. Simpson,
unpublished data). This process involves binding of polypep-
tide to the apical surface, endocytosis, and transcytosis, fol-
lowed by release of polypeptide on the basolateral surface.
Therefore, experiments to assess the abilities of BoNT/B HC50
and BoNT/E HC50 to cross epithelial barriers were performed.
T-84 cells were grown in a Transwell apparatus, as described
in Materials and Methods. BoNT/B holotoxin and its HC50
domain, as well as BoNT/E holotoxin and its HC50 domain,
were added to the apical surface of epithelial cells, and the
FIG. 3. Immunoglobulin responses to the HC50 domain of BoNT/A
administered as an injection (i.m.) vaccine. The polypeptide was given
to mice (10 mice per group) in the absence (open symbols) or in the
presence (solid symbols) of an adjuvant (alum). (a) Magnitudes of IgG
responses. (b) Magnitudes of IgA responses. The adjuvant enhanced
the responses to both classes of immunoglobulin, and the magnitude of
the enhancement was substantial for IgA.
FIG. 4. Immunoglobulin responses to the HC50 domain of BoNT/A
when it was administered as a mixed-mode vaccine. The polypeptide
was given to mice (n  10) in an initial i.m. injection with alum as an
adjuvant and in two subsequent i.n. boosters with vitamin E as an
adjuvant. The results demonstrated that the mixed-mode vaccination
paradigm elicited substantial IgG (}) and IgA (F) responses.
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accumulation of these polypeptides on the basal side of cells
was monitored. Parallel experiments were done with BoNT/A
holotoxin and its HC50 domain for comparison. The results
(Fig. 5) revealed that the HC50 subunit of each serotype and
the homologous neurotoxin at an equimolar concentration
were comparable in terms of the ability to penetrate monolay-
ers of human epithelial cells. These results make it clear that
the minimum essential domain for transcytosis of each sero-
type is localized in the HC50 domain.
Transcytosis in the presence of multiple serotypes. Research
on multivalent vaccines appears to reflect two expectations: (i)
vaccination should evoke resistance to multiple serotypes of
toxin, but (ii) protection is needed for only one serotype at a
time. Although it is appropriate to expect that a multivalent
vaccine will provide protection against several serotypes, it may
not be appropriate to expect that a bioterrorism or biological
warfare incident will involve only one serotype at a time.
Therefore, experiments were performed to monitor transcyto-
sis of multiple serotype polypeptides given together.
Figure 6 shows the results of experiments in which the three
serotypes of greatest concern to human health (serotypes A, B,
and E) were added simultaneously to the apical surfaces of
epithelial cells. As this figure shows, the transcytosis of each
HC50 domain remained constant, regardless of whether the
domain was added alone or with other domains.
Multiple HC50 domains can be administered simulta-
neously to create a multivalent mucosal vaccine. The HC50
domains of BoNT/A, BoNT/B, and BoNT/E were administered
together (20 g each) in the presence of vitamin E as an i.n.
vaccine. A total of 20 mice were vaccinated. At the end of the
protocol, animals were randomly assigned to two groups con-
taining 10 mice each that were challenged by the i.n. route or
the i.p. route.
The ELISA data indicated that all three antigens evoked a
substantial IgG response (Fig. 7a) and a substantial IgA re-
sponse (Fig. 7b). These data provide further support for the
premise that combined administration of three antigens does
not lead to inhibition of absorption of any one of the antigens.
Also, as a comparison of Fig. 7 with Fig. 2 shows, the magni-
tude of the immunoglobulin response for an individual antigen
in the trivalent formulation (e.g., BoNT/A HC50) was in the
same range as the magnitude of the immunoglobulin response
for the individual antigen in a monovalent formulation. Thus,
FIG. 5. Transcytosis of BoNT/A HC50 (gel A), BoNT/B HC50 (gel
B), and BoNT/E HC50 (gel E). Equimolar concentrations of the three
polypeptides (1  108 M) or the corresponding parent toxins were
added to the upper wells of T-84 monolayers in a Transwell apparatus,
and the accumulation in the lower wells was assayed by Western
blotting. Lane 1, holotoxin added; lane 2, HC50 domains added. Note
that the levels of transcytosis for each holotoxin and its HC50 domain
were comparable.
FIG. 6. Individual and combined rates of transcytosis of BoNT/A
HC50 (gel A), BoNT/B HC50 (gel B), and BoNT/E HC50 (gel E). Equimo-
lar concentrations of the three polypeptides (1 108 M) were added to
the apical surfaces of T-84 monolayers, and the accumulation of the
polypeptides on the basal side of the cells was assayed by Western blotting.
Lane 1, HC50 domain added alone; lane 2, three HC50 domains added
together. The results indicate that simultaneous addition of HC50 domains
did not inhibit or reduce the extent of transcytosis of any of the domains.
FIG. 7. Immunoglobulin responses to i.n. administration of a triva-
lent vaccine. The HC50 domains of three serotypes were administered
as described in the text, and the magnitudes of the IgG responses (a)
and IgA responses (b) were determined. The results indicate that all three
antigens evoked substantial responses. Œ, BoNT/A; f, BoNT/B; F, BoNT/E.
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simultaneous administration of multiple antigens did not result
in immune suppression.
Mice were challenged by two routes with BoNT, i.p. (n 10)
and i.n. (n  10). For each route of administration, half of the
mice received 1  103 mouse LD50 (n  5), and the other half
received 1  104 mouse LD50 (n  5). In addition, animals
were challenged simultaneously with all three serotypes (sero-
types A, B, and E), and thus the cumulative dose was either
3  103 LD50 or 3  10
4 LD50. Control animals that received
either 3  103 or 3  104 LD50 became seriously ill within
minutes. By contrast, all vaccinated animals survived at least 1
week, regardless of the dose or the route of challenge. This
means that not only were animals protected against a substan-
tial monovalent challenge, but they were also protected against
a substantial polyvalent challenge.
HC50 domains of BoNT/A, BoNT/B, and BoNT/E can be
administered simultaneously to create a multivalent mixed-
mode vaccine. Mice were vaccinated by combining an initial
injection of antigens with two subsequent i.n. administrations
of antigens. For the initial i.m. injection, all three antigens (20
g each) were mixed with alum prior to administration. For
the subsequent boosters, all three antigens (20 g each) were
mixed with vitamin E prior to administration. Fourteen days
after the last booster, aliquots of blood were obtained to de-
termine the circulating titers of IgG and IgA. At the same time,
animals were randomly assigned to two groups (10 mice per
group) for inhalation challenge and i.p. challenge.
The results obtained with the multivalent mixed-mode vac-
cine (Fig. 8a and b) were similar to the results obtained with
the multivalent mucosal vaccine (Fig. 7a and b). Thus, all three
of the HC50 domains evoked substantial IgG and IgA re-
sponses.
Mice were challenged with toxin by two routes of adminis-
tration, as described above. As before, animals received a com-
bination challenge in which serotype A, B, and E toxins were
given together (1  104 mouse LD50 each). Similar to the
results obtained with mucosal vaccination, the results obtained
with mixed-mode vaccination revealed that all control animals
quickly became ill (
80 min), whereas the vaccinated animals
survived without signs of illness (1 week).
Antibodies can associate with toxin to block binding and
transcytosis across epithelial cells. There are several possible
mechanisms by which antibodies directed against BoNT can
diminish or eliminate the lethal effects of the molecule. One
obvious possibility is that these antibodies bind at or near the
toxin domain responsible for association with epithelial cells,
which in turn would block absorption of the toxin molecule.
This possibility was assessed by using BoNT/A as a prototype.
There are two potential sources of antibody that could act to
block toxin absorption: (i) secretory IgA generated in the lu-
men of the airway and (ii) circulating immunoglobulin that is
transported into the lumen. Experiments described above dem-
onstrated that mucosal vaccination led to a robust circulating IgA
response. It was necessary to show that an identical vaccination
paradigm would elicit a strong secretory IgA response.
Mice (n  5) were vaccinated i.n. using BoNT/A HC50 as a
prototype. As described above, there was an initial administra-
tion, followed by two boosters (20 g per administration), each
of which was given with vitamin E as an adjuvant. Two weeks
after the final boost, animals were sacrificed, and BAL samples
were obtained. The ELISA titers for antigen-specific secretory
IgA revealed that there was a substantial response (Fig. 9).
FIG. 8. Immunoglobulin responses to mixed-mode administration
of a trivalent vaccine. The HC50 domains of three serotypes were
administered as described in the text, and the magnitudes of the IgG
responses (a) and IgA responses (b) were determined. The results
clearly show that all three antigens evoked substantial responses. Œ,
BoNT/A; f, BoNT/B; F, BoNT/E.
FIG. 9. Mucosal antibody responses to vaccination with BoNT/A
HC50. The antigen was administered as an i.n. vaccine in combination
with vitamin E, and the magnitude of the secretory IgA response was
determined (f). The data show that there was a substantial response.
A matched group of animals was vaccinated by the i.m. route (antigen
plus alum), and again the responses were measured. As expected,
parenteral administration of the HC50 domain did not evoke a signif-
icant mucosal antibody response (F). O.D., optical density.
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Secretory IgA (0.1 ml of lavage fluid) or a combination of
circulating IgG and IgA (0.1 ml of antiserum) was obtained
from vaccinated animals and incubated with BoNT/A (1 
108 M). After 30 min, the mixtures were added to the apical
surfaces of T-84 monolayers in a Transwell apparatus. Medium
in the basal chamber was collected and handled as described in
Materials and Methods. Aliquots were used for Western blot
analyses, as shown in Fig. 10. As expected, untreated toxin was
able to bind to and penetrate epithelial barriers, whereas an-
tibody-pretreated toxin had virtually no ability to cross these
barriers.
Antiserum from immunized animals promotes toxin clear-
ance from the general circulation and enhances accumulation
in the liver and spleen. Control mice (three or more mice per
group) received a single intravenous bolus of 125I-labeled
BoNT/A, and 30 min after this aliquots of blood were collected
and assayed to determine the presence of toxin. The total
duration of the experiment was (i) less than the half-time for
toxin elimination from the general circulation and (ii) less than
the time necessary for significant metabolic transformation of
toxin in blood (29). Experimental animals received an equiva-
lent dose of toxin that had been preincubated with a neutral-
izing dose of antiserum collected from animals that received
trivalent vaccine (0.01 ml; 30 min of incubation; room temper-
ature). The data revealed that neutralizing antibody greatly
increased the rate of toxin clearance from the blood (Fig. 11).
The toxin levels in the blood and serum of experimental ani-
mals were approximately 1 order of magnitude less than those
in control animals.
The BoNT molecule (ca. 150 kDa), especially when the toxin
molecule is decorated with antibody, is too large to undergo
significant renal clearance. On the other hand, hepatic uptake
and splenic uptake are likely mechanisms for clearance of an
antigen-antibody complex. Therefore, 125I-labeled BoNT/A
was injected into control animals and vaccinated animals as
described above, and 30 min later the animals were anesthe-
tized and perfused. The livers and spleens were subsequently
excised and assayed to determine the accumulation of toxin
(Fig. 12a). In control animals the percentage of the total dose
administered that could be recovered in the liver was 4.43%,
and in experimental animals the percentage that could be
recovered in the liver was 48.3%; the difference was quantita-
tively (ca. 11-fold) and statistically (P 
 0.001) significant.
Similarly, the percentage of the total dose administered that
could be recovered in the spleens of control animals was 0.3%,
whereas the percentage that could be recovered in the spleens
of experimental animals was 3.6%; the difference was also
quantitatively (12-fold) and statistically (P
 0.001) significant.
The levels of labeled BoNT/A were also determined for four
other tissues (kidney, lung, heart, and brain). As shown in Fig.
12b, neutralizing antiserum did not result in enhanced accu-
mulation of toxin in any of these tissues.
Antibodies from immunized animals can block the neuro-
paralytic actions of BoNT. The HC50 domain of BoNT is
known to possess the molecular determinants that govern toxin
binding to neuronal membranes (31). This raises the possibility
that at least one of the clonal antibodies in the serum of
immunized animals could associate with the toxin in a way that
would block toxin binding and/or block toxin internalization.
To test the possibility that antiserum directed against HC50
could antagonize toxin-induced paralysis, unlabeled BoNT/A
(1  108 M) was incubated without or with mouse trivalent
antiserum (0.1 ml; 30 min; room temperature). The mixtures
were subsequently diluted and added to murine phrenic nerve-
hemidiaphragm preparations (four preparations per group) to
obtain a final toxin concentration of 1  1011 M. The results
(Fig. 13) demonstrated that the paralysis times for control
tissues were ca. 100 to 140 min. Tissues that were treated with
toxin that had been preincubated with immune serum showed
no onset of neuromuscular blockade during a 100- to 140-min
period.
DISCUSSION
BoNT is the etiologic agent that causes the disease botulism.
This disease can occur naturally, but it can also be a result of
FIG. 10. Effect of neutralizing antibodies on binding and transcy-
tosis of BoNT/A. Toxin (1  108 M) was incubated alone or with
BAL samples (0.1 ml) or antiserum (0.1 ml) obtained from mice that
had been immunized with BoNT/A HC50 vaccine. After incubation
(1 h), the solutions were added to apical wells containing monolayers
of epithelial cells, and transcytosis was monitored. The results demon-
strated that untreated toxin crossed epithelial barriers (lane 1) but
antibody-pretreated toxin did not cross these barriers (lane 2, anti-
serum; lane 3, BAL sample).
FIG. 11. Effect of neutralizing antibodies on the circulating levels
of BoNT/A. 125I-labeled BoNT/A was incubated alone (open bars) or
with antiserum (cross-hatched bars) from animals that had been im-
munized with trivalent mucosal vaccine (0.01 ml; 30 min; room tem-
perature). Mice were injected intravenously with the material, and 30
min later samples of blood were collected. The results demonstrated
that neutralizing antibodies resulted in a dramatic reduction in blood
and serum levels of toxin.
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bioterrorism or biological warfare. The number of outbreaks of
naturally occurring botulism and the number of cases per out-
break are too low to be a driving force in the development of
a vaccine. On the other hand, concern about the potential use
of the toxin in acts of bioterrorism or biological warfare has
served as a powerful motivation to develop a vaccine.
Although it is understandable that there is a sense of ur-
gency concerning the need for a vaccine, this should not ob-
scure the fact that development of the final product should be
governed by the principles of rational vaccine design. Two of
the most important areas in which these principles should
apply are (i) the selection of an antigen and (ii) the selection of
a route of administration for that antigen.
Selection of an antigen. In historical attempts to develop a
botulinum vaccine workers focused on chemical toxoids (i.e.,
formalin inactivation of impure toxin preparations), whereas in
more recent attempts workers have focused on recombinant
toxoids (6). Vaccine candidates in the latter category have
included the holotoxin with point mutations to eliminate cat-
alytic activity (15) and various subunit polypeptides. The sub-
unit vaccine that has emerged as the favored candidate is HC50
(also known as HCC and fragment C [6]).
There are a variety of reasons to believe that HC50 is a
rational choice. To begin with, it is modeled after an analogous
polypeptide from tetanus toxin that has been shown to be a
highly efficacious vaccine against the parent molecule (10, 13,
20). In addition, the HC50 domain of BoNT has a large number
of epitopes. In fact, there are more epitopes in this polypeptide
than there are in the rest of the toxin molecule combined (7).
This suggests that (i) this polypeptide should evoke a robust
polyclonal response against the native toxin and (ii) increasing
the length of the polypeptide (HC66, HC88, etc.) may not lead
to increases in resistance that would be clinically significant.
These observations, combined with reports that HC50 is an
efficient immunogen in laboratory animal studies, strongly sup-
FIG. 12. Effects of neutralizing antibodies on the accumulation of
toxin in various tissues. 125I-labeled BoNT/A was incubated alone
(open bars) or with antiserum (cross-hatched bars) and administered
as described in the legend to Fig. 11. After 30 min, animals were
anesthetized and perfused for subsequent removal of organs. The data
show that pretreatment of toxin with neutralizing antibodies resulted
in marked increases in the accumulation in livers and spleens (a).
Antibody pretreatment did not increase the accumulation in tissues
that are ordinarily not related to immune processing (b).
FIG. 13. Effects of neutralizing antibodies on the neuromuscular blocking properties of BoNT/A. Toxin (1  108 M) was incubated alone or
with antiserum from animals that had been immunized with trivalent vaccine (0.1 ml; 30 min; room temperature). The mixtures were then added
to phrenic nerve-hemidiaphragm preparations (four preparations per group) to obtain a final toxin concentration of 1  1011 M. Untreated toxin
caused paralysis of transmission (i.e., a 90% reduction in twitch amplitude) within 100 to 140 min (}). In the same time frame, antibody-pretreated
toxin did not paralyze transmission (Œ). An equivalent experiment was done in which toxin was preincubated with preimmune serum (inset). This
pretreatment did not significantly affect the potency of the toxin.
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port the premise that a rational vaccine candidate has been
identified. However, there is even more evidence that supports
the use of this subunit vaccine. As previously reported, the
HC50 domain of BoNT/A possesses all of the structural infor-
mation necessary for binding to and penetration of gut and
airway epithelial barriers (23). This means that the BoNT/A
HC50 domain can simultaneously serve as a delivery device and
as an immunogen in a mucosal botulinum vaccine.
Selection of a route of administration. There are at least two
powerful reasons to seek a mucosal (“needle-free”) vaccine
against BoNT. One of these reasons is broad and is related to
the discipline of immunology; the second is highly specific and
is related to the mechanism of BoNT action. In broad terms,
there is wide recognition in the field of immunology that in-
jectable vaccines should give way to needle-free vaccines (24).
Indeed, every major health care entity that supports vaccine
research, including the National Institutes of Health, the
World Health Organization, and the Bill and Melinda Gates
Foundation, has encouraged efforts to develop needle-free ap-
proaches. The reasons for this are compelling, and they include
(i) the reduced need for, and cost of, health care personnel; (ii)
the elimination of accidental needle sticks and their potential
contribution to blood-borne diseases; (iii) the reduced burden
of storing medical waste; and (iv) the elimination of the po-
tential for environmental contamination. There is no reason
why a vaccine against BoNT should be exempt from these
considerations.
The second reason for pursuing a mucosal vaccine is related
specifically to the mechanism of toxin action. The majority of
all reported cases of naturally occurring botulism are due to
mucosal exposure, and it is anticipated that most if not all cases
of a potential bioterrorism incident or biological warfare inci-
dent would also be due to mucosal exposure. This is a strong
argument against an injection vaccine and in favor of a mucosal
vaccine, because the latter has the potential to act in the lumen
of the gut and airway to evoke the production of antibodies
(i.e., secretory IgA) that could block absorption of the toxin.
An injection vaccine does not have this benefit.
To return to a point discussed above, the HC50 domain may
be an ideal choice as a mucosal vaccine, because this molecule
has the properties of both an immunogen and a delivery de-
vice. These dual functions represent a major advance over
current efforts to develop a mucosal vaccine. For example, use
of the recombinant polypeptide obviates the need for chemi-
cally induced toxoids (16). Similarly, the inherent ability of the
polypeptide to penetrate epithelial barriers and evoke an im-
mune response circumvents the need for ancillary devices, such
as a virus (19).
Identification of a mucosal vaccine. The data presented in
this paper demonstrate that the HC50 domain is an effective
inhalation vaccine. In an initial series of experiments utilizing
BoNT/A as a prototype, the HC50 domain evoked a significant
IgG response and a more modest IgA response. It also pro-
vided resistance against a challenge dose of BoNT.
One well-recognized approach for enhancing an immuno-
globulin response is to combine the antigen of interest with an
adjuvant. This concept is technically sound, but it presents a
difficulty in the context of trying to develop a vaccine that can
be licensed for human use. Almost all agents that have been
examined as mucosal adjuvants, such as the cholera toxin B
subunit, are not approved for clinical use. One potential solu-
tion to this problem is to select an agent for which there are a
minimum of regulatory obstacles. Therefore, we used vaccina-
tion protocols in which two natural products (chitosan and
vitamin E) were evaluated to determine their utility as adju-
vants (2, 8, 25, 36). Administration of the HC50 domain of
BoNT/A simultaneously with chitosan or with vitamin E (Fig.
2) had the intended effect of boosting the levels of the immu-
noglobulin responses.
Trivalent vaccine against botulism. BoNT serotypes A, B,
and E are the serotypes most often implicated in human illness.
This suggests that the greatest need is for a multivalent prep-
aration that provides protection against all three of these se-
rotypes. This goal appears to be attainable, because (i) the
HC50 domains of these serotypes are able to penetrate epithe-
lial barriers (Fig. 5) and (ii) the same domains are immunogens
that evoke protection against the corresponding parent toxins
(Fig. 7). This is an encouraging basis on which to seek a
trivalent vaccine, but at the same time it leaves three important
questions unanswered. First, can HC50 domains given in com-
bination penetrate epithelial barriers as well as HC50 domains
given individually? Second, can HC50 domains given in com-
bination evoke an immune response comparable to that
evoked by peptides that are given individually? Third, can a
trivalent vaccine evoke resistance of a magnitude sufficient to
afford protection against a combination challenge?
The question about membrane penetration has been ad-
dressed using monolayers of human epithelial cells. These cells
have proven to be useful in studies in which the kinetics of
BoNT/A binding and transcytosis have been analyzed, as well
as in studies in which BoNT/A molecules crossing epithelial
barriers have been visualized (1, 22). This work was extended
here to include the HC50 domains of BoNT/B and BoNT/E. In
the context of vaccine research, the important observation
resulting from these experiments is that each HC50 domain
retained its characteristic ability to cross epithelial barriers,
even when it was added along with other such domains (Fig. 6).
This is predictive evidence that the three domains could be
administered as a trivalent vaccine.
The question about immunogenicity was answered by coad-
ministration of the three HC50 domains by two regimens, mu-
cosal vaccination alone and an initial injection followed by
mucosal boosters. Interestingly, these two approaches pro-
duced very similar outcomes. Both resulted in substantial IgG
and IgA responses. Using BoNT/A HC50 as an indicator, one
can deduce that the magnitudes of the immunoglobulin re-
sponses for monovalent vaccination (Fig. 2) and trivalent vac-
cination (Fig. 7 and 8) were not significantly different. The data
indicate that simultaneous vaccination with three antigens did
not compromise the ability of the immune system to respond to
any one of the antigens.
Finally, the question about induced resistance was answered
by challenging animals with a mixture of the three holotoxins.
Equal doses of the holotoxins were mixed to produce final
doses of 3  103 or 3  104 LD50. Regardless of whether
animals received the trivalent vaccine by mucosal administra-
tion or by mixed-mode administration, all test animals sur-
vived. These data demonstrate that a trivalent vaccine that acts
by the mucosal route has been identified.
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Mechanisms of resistance. There are a number of mecha-
nisms by which immunoglobulin-mediated resistance could de-
crease toxicity. The sequence of events that underlies toxin
action suggests that an ideal vaccine candidate should possess
at least three of these mechanisms. A clonal population should
possess within it antibodies that act (i) in the lumen of the gut
or airway to block toxin absorption, (ii) in the general circula-
tion to enhance clearance from the blood and accumulation in
the liver and spleen, and (iii) at the neuromuscular junction to
antagonize blockade of exocytosis. The clonal population
evoked by trivalent vaccination had in it antibodies that could
be shown to act at all three sites.
When tested with a model system for binding and transcy-
tosis in human epithelial cells, both BAL samples (secretory
IgA) and antiserum (circulating IgG and IgA) from animals
that had received HC50 as a vaccine blocked the ability of
BoNT to cross epithelial barriers (Fig. 10). The results indi-
cated that the level of inhibition of binding and transcytosis
was greater than 99%. If this outcome were a close approxi-
mation of events in vivo, it would mean that mucosal immunity
in the lumen of the gut or airway can be an important factor
contributing to resistance.
In related experiments, the pharmacokinetics of BoNT/A
elimination were studied using control and experimental ani-
mals. The experiments were conducted over a period of time
(30 min) during which the fractional distribution of toxin out of
the circulation and into peripheral cholinergic nerve endings of
control animals had not yet produced serious neuromuscular
blockade (29). These experiments demonstrated that a neu-
tralizing dose of trivalent antiserum resulted in a rapid and
dramatic increase in the rate of clearance of BoNT/A from the
blood (Fig. 11). This phenomenon was accompanied by an
equally dramatic accumulation of toxin in the liver and spleen
(Fig. 12). It is very likely that hepatic and splenic accumulation
is a prelude to metabolic degradation and eventual systemic
elimination of toxin fragments.
The final mechanism by which an ideal vaccine candidate
could evoke immunoresistance is antagonism of toxin-induced
neuromuscular blockade (31, 32). The possibility that this oc-
curs was tested by using an isolated phrenic nerve-hemidia-
phragm preparation, which means that mechanisms such as
inhibition of luminal absorption and enhancement of systemic
clearance could not have contributed to the outcome. These
experiments clearly demonstrated that anti-HC50 antibodies
antagonized toxin action in isolated neuromuscular prepara-
tions.
Concept of a universal vaccine. The discipline of immunol-
ogy typically uses the term “universal vaccine” to convey one of
two concepts: (i) a single antigen can be administered by all of
the routes that are commonly used for vaccines or (ii) a single
antigen can be used to evoke resistance to multiple strains,
serotypes, or other variants of a pathogen. The data suggest
that the HC50 domain is close to satisfying the expectation for
a single antigen that is active when it is administered by mul-
tiples routes.
Numerous investigators have contributed to the observation
that the HC50 domain of all BoNT serotypes can be adminis-
tered by injection to evoke an immune response. It has also
been shown that the inactive holotoxin, the entire HC, and the
HC50 domains of several serotypes are active when they are
administered by the oral and/or inhalation routes (see the
Introduction). In addition, a single paradigm that incorporates
both injection and nasal routes of administration can evoke
robust immunity (this study).
It is customary to divide routes of potential vaccine admin-
istration into three broad categories: injection, mucosal, and
cutaneous (24). As mentioned above, the HC50 domain of
BoNT is already known to be effective as an injection vaccine,
a mucosal vaccine, and a mixed-mode vaccine. To date, the
HC50 domain has not been shown to be a cutaneous vaccine. In
fact, this domain by itself does not penetrate the stratum cor-
neum (unpublished data). However, there have been several
recent and notable advances in the transcutaneous delivery of
antigens. Therefore, vaccination protocols aimed at transcuta-
neous delivery of HC50 are currently being investigated, in the
hope of establishing that HC50 is a true universal vaccine.
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